Knockdown of Aurora-A sensitizes glioblastoma cells to TMZ in mice. (A) Female nude mice at 6–8 weeks of age were implanted subcutaneously with U251 cells. A total of 7 days after tumor cells were implanted, the mice were assigned randomly to five groups and treated with an shAurora-A/liposome or shCtrl/liposome complex, combined with or without TMZ. Tumor volume was recorded during the treatment and growth curves were constructed. Values are presented as the mean ± SD (n=5). **P<0.01 compared with shCtrl group; ##P<0.01 compared with TMZ group. (B) A total of 3 days after the final treatment, mice were sacrificed and subcutaneous tumors were weighed. Values are presented as the mean ± SD (n=5). **P<0.01 compared with shCtrl group; ##P<0.01 compared with TMZ group. (C and D) The TUNEL assay was performed to detect apoptotic cells in primary U251 xenografts (magnification, ×100). The apoptotic index was calculated as a ratio of the apoptotic cell number to the total cell number in each field. Values are presented as the mean ± SD (n=5). **P<0.01 compared with shCtrl group; ##P<0.01 compared with TMZ group. (E) Cluster of differentiation 31 staining was performed to detect angiogenesis in primary U251 xenografts (magnification, ×200). (F) The microvessel density was calculated. Values are presented as the mean ± SD (n=5). **P<0.01 compared with shCtrl group; *P<0.05 compared with shCtrl group; ##P<0.01 compared with TMZ group. TMZ, temozolomide; sh, short hairpin; SD, standard deviation; DMSO, dimethyl sulfoxide; Ctrl, control.